NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Drug Manufacturers - Specialty & Generic · USD

Haleon plc (HLN) Stock Analysis

Haleon plc (HLN) is a Drug Manufacturers - Specialty & Generic stock listed on NYSE and quoted in US Dollar.

HLN

$9.60

−$0.26 (−2.64%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare HLN with… →

HLN Key Statistics

As of Sep 4, 2026
Trading
Open
$9.61
Previous Close
$9.86
Day's Range
9.57–9.74
52-Week Range
8.65–11.28
Volume
18.17M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.24
Valuation
Market Cap
$42.22B
P/E Ratio
20.00
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
15.38
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
2.27
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.79
EPS (ttm)Profit attributable to each share over the last twelve months.
0.48
Financials (FY)
Revenue (FY)
$11.03B−1.81%
Net Income (FY)
$1.67B+15.60%
Profit marginThe share of revenue left as profit after all costs and taxes.
14.55%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
4.40B
1-Year Return
−1.15%
Dividend and dates
Dividend
$0.20+2.06%
Ex-Dividend Date
August 14, 2026
Avg Volume
9.87M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

HLN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−3.79%
2025+7.85%
2024+17.98%
2023+4.22%
2022 (partial year)+9.59%

As of September 4, 2026.

HLN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$11.03B$1.67B15.1%
2024$11.23B$1.44B12.8%
2023$11.30B$1.05B9.3%
2022$10.86B$1.06B9.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$11.03B$7.08B$2.41B$1.67B15.1%
2024$11.23B$6.82B$2.21B$1.44B12.8%
2023$11.30B$6.75B$2.00B$1.05B9.3%
2022$10.86B$6.58B$1.83B$1.06B9.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

HLN Dividend History

$0.18+12.1% vs 2024

Dividends per share, 2025 · 2 payments

YearDividends per sharePaymentsChange
2026*$0.202—
2025$0.182+12.1%
2024$0.162+51.0%
2023$0.102—

Most recent payment: $0.10 per share, ex-dividend August 14, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

HLN Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricHLNDrug Manufacturers - Specialty & Generic medianvs median
P/E20.0019.274% above
P/S ratio3.792.3065% above
Profit margin14.55%−3.14%17.7 pts above

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Haleon plc (HLN) at $42.22B. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. Headcount on file is 24,535.

The 52-week range on file runs from $8.65 to $11.28. HLN last closed at $9.60 on September 4, 2026. That is −$0.26 (−2.64%) against the previous close. The latest close sits 10.98% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $11.03B. Against the prior fiscal year total of $11.23B, that is a change of −1.81%. The same year closed with net income of $1.67B. That is +15.60% against the prior fiscal year. The reported profit margin is 14.55%. That is 17.7 percentage points above the Drug Manufacturers - Specialty & Generic median of −3.14%. Trailing earnings per share are 0.48.

Across the 4 fiscal years on file, revenue moves from $10.86B in 2022 to $11.03B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 20 times earnings. That is 3.82% above the Drug Manufacturers - Specialty & Generic median of 19.27. On forward earnings the ratio is 15.38. The PEG ratio, which sets the P/E against expected earnings growth, reads 2.27. Measured against sales, the shares trade at 3.79 times revenue. On price-to-sales that is 64.86% above the Drug Manufacturers - Specialty & Generic median of 2.3. 103 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

The reported beta is 0.25. Annualized volatility over the trailing 4 years is 22.6%. The trailing one-year price return is −1.15%. Measured over 3 years, that is +7.55% a year compounded.

Growth & Income

HLN pays a dividend yielding 2.06%. At the indicated rate that is $0.20 a share a year. The ex-dividend date on file is August 14, 2026. Dividends are recorded for 4 calendar years; 2026 shows 2 payments totalling $0.20 a share. The year before, 2025, totalled $0.18 a share.

So far in 2026 the price is −3.79%. Across the complete calendar years on file, 2024 returned +17.98% and 2023 returned +4.22%. Of the 3 complete calendar years on file, 3 finished higher.

Peer Comparison

Haleon plc (HLN) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Haleon plc HLN $42.22B 20.0
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Zoetis Inc. ZTS $31.33B 12.4

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Haleon plc trades at a P/E of 20.0.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B

 NBIX

Neurocrine Biosciences, Inc.

$15.82B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Haleon plc

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc has a collaboration agreement with Microsoft to scale digital, data and AI capabilities across the business and accelerate delivery of its global win as one strategy. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.

Visit website →